Curiously, chills was one of the most common adverse events in participants with cutaneous T-cell lymphoma who received the Resimmune, which is a second-generation recombinant immunotoxin composed of the catalytic and translocation domains of diphtheria toxin fused to two single-chain antibody fragments reactive with the extracellular domain of CD3ε (35). The gene discussed is CD3E; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.